Evidence map›Paper›PMID 33173481›Full record

ArticleCase reports in oncology

Ogilvie Syndrome in a Refractory Germ Cell Tumor Treated with Vinblastine, Ifosfamide and Cisplatin Regimen.

Hrishi Varayathu, Mansi Sandip Shah, Vinu Sarathy, Beulah Elsa Thomas, Vinayak Munirathnam, Shivakumar Swamy Shivalingappa, Radheshyam Naik

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hrishi VarayathuDepartment of Translational Medicine and Therapeutics, Healthcare Global Enterprises Limited, Bangalore, India.
Mansi Sandip ShahDepartment of Medical Oncology, Healthcare Global Enterprises Limited, Bangalore, India.
Vinu SarathyDepartment of Medical Oncology, Healthcare Global Enterprises Limited, Bangalore, India.
Beulah Elsa ThomasDepartment of Clinical Pharmacology, Healthcare Global Enterprises Limited, Bangalore, India.
Vinayak MunirathnamDepartment of Medical Oncology, Healthcare Global Enterprises Limited, Bangalore, India.
Shivakumar Swamy ShivalingappaDepartment of Radiology, Healthcare Global Enterprises Limited, Bangalore, India.
Radheshyam NaikDepartment of Medical Oncology, Healthcare Global Enterprises Limited, Bangalore, India.
Healthcare Global Enterprises · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ogilvie syndrome or intestinal pseudo-obstruction is a clinical syndrome characterized by autonomic imbalance affecting peristalsis of colon leading to obstructive signs and symptoms. The etiologies commonly implicated are drugs affecting the cholinergic system, narcotics, electrolyte imbalance, severe sepsis, cancer, major surgery, and renal and cardiac failure. Ogilvie syndrome secondary to chemotherapy is a very rare phenomenon with very few reports in the literature. Cisplatin-induced neuropathy has been reported to occur when the cumulative dose exceeds 360 mg/m

Indexed as

Autonomic neuropathyCumulative toxicityDrug-induced Ogilvie syndromePeripheral neuropathy

Identifiers

PMID33173481
PMCPMC7588742
OpenAlexW3089634777

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.